We are live on ! Find out more
DGM

Darwin Global Management Portfolio holdings

AUM $3.77B
1-Year Est. Return 307.72%
This Fund
S&P 500
This Quarter Est. Return
-3.24%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
-$1.17B
Cap. Flow
-$565M
Cap. Flow %
-14.98%
Top 10 Hldgs %
100%
Holding
9
New
3
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$223M
2
ROIV icon
Roivant Sciences
ROIV
+$175M
3
ABVX
Abivax
ABVX
+$34.3M
4
BLTE
Belite Bio
BLTE
+$5M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$1.01M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$635M
2
CDTX
Cidara Therapeutics
CDTX
+$220M
3
WVE icon
Wave Life Sciences
WVE
+$125M
4
CAPR icon
Capricor Therapeutics
CAPR
+$23.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.5B
$2.58B 68.33%
16,805,184
-4,128,093
-20% -$635M
BLTE
2
Belite Bio
BLTE
$6.02B
$456M 12.1%
3,057,412
+29,708
+1% +$5M
ABVX
3
Abivax
ABVX
$11.9B
$352M 9.34%
3,468,657
+290,156
+9% +$34.3M
RVMD icon
4
Revolution Medicines
RVMD
$39.6B
$205M 5.44%
+2,211,018
New +$223M
ROIV icon
5
Roivant Sciences
ROIV
$24.8B
$180M 4.76%
+6,797,300
New +$175M
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.77B
$1.46M 0.04%
+17,357
New +$1.01M
CAPR icon
7
Capricor Therapeutics
CAPR
$1.13B
– –
-800,000
Closed -$23.2M
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
– –
-997,196
Closed -$220M
WVE icon
9
Wave Life Sciences
WVE
$1.12B
– –
-7,298,421
Closed -$125M

Similar funds

VVP
Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return
ABC
Associated Banc-Corp Green Bay, Wisconsin $3.78B AUM 21.74% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $3.76B AUM 23.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
VA
VestGen Advisors Inverness, Illinois $3.76B AUM 26.04% 1-Year Est. Return
GCC
Guardian Capital (Canada) Toronto, Ontario, Canada $3.78B AUM 33.04% 1-Year Est. Return
SB
SIG Brokerage New York $3.79B AUM 44.46% 1-Year Est. Return

Darwin Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Darwin Global Management held 9 positions worth $3.77B, down 24% from $4.94B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Darwin Global Management withdrew a net $565M in Q1 2026, closing 3 positions and reducing 1 holding. Its most notable exit was Cidara Therapeutics, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Darwin Global Management opened a new position in Revolution Medicines worth $205M.

  • Darwin Global Management's largest Q1 2026 buy was Revolution Medicines: 2,211,018 shares worth $205M.
  • Darwin Global Management added most to Abivax in Q1 2026, an estimated $34.3M increase.
  • Darwin Global Management's biggest Q1 2026 reduction was Insmed, cutting an estimated $635M.
  • Darwin Global Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $220M.
  • Darwin Global Management's ten largest holdings make up 100% of its $3.77B portfolio in Q1 2026.
  • Darwin Global Management opened 3 new positions and closed 3 in Q1 2026.
  • Darwin Global Management's portfolio value fell 24% quarter-over-quarter to $3.77B.

Based on Darwin Global Management's 13F filing for Q1 2026, filed 15 May 2026.